DLX3 Human shRNA Plasmid Kit (Locus ID 1747)

CAT#: TL319765

DLX3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 1747
• Synonyms: AI4; TDO
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol (34 ug/ml)
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: DLX3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1747). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_005220, NM_005220.1, NM_005220.2, BC028970, BC028970.1, BC012361, BM982262
• UniProt ID: O60479
• Summary: Many vertebrate homeo box-containing genes have been identified on the basis of their sequence similarity with Drosophila developmental genes. Members of the Dlx gene family contain a homeobox that is related to that of Distal-less (Dll), a gene expressed in the head and limbs of the developing fruit fly. The Distal-less (Dlx) family of genes comprises at least 6 different members, DLX1-DLX6. Trichodentoosseous syndrome (TDO), an autosomal dominant condition, has been correlated with DLX3 gene mutation. This gene is located in a tail-to-tail configuration with another member of the gene family on the long arm of chromosome 17. Mutations in this gene have been associated with the autosomal dominant conditions trichodentoosseous syndrome and amelogenesis imperfecta with taurodontism. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).